<DOC>
	<DOCNO>NCT01051206</DOCNO>
	<brief_summary>HES 130/0.4 significantly solution affect coagulation blood loss patient medicate antiplatelet agent prior off-pump coronary bypass surgery ( OPCAB ) .</brief_summary>
	<brief_title>The Effect 6 % Hydroxyethyl Starch 130/0.4 Blood Loss Coagulation Patients Medicated With Antiplatelet Agents Prior Off-Pump Coronary Bypass Graft Surgery</brief_title>
	<detailed_description />
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
	<criteria>Eighty patient undergo OPCAB , expose anti platelet agent 5 day prior surgery randomly allocate infuse HES 130/0.4 30 ml/kg follow crystalloid infusion infuse crystalloid perioperative period , Patient Valvular disease heart MI within 3 month , patient 40 % leave ventricle preoperative output leave main artery stenosis anemia ( hemoglobin &lt; 12 g/dl ) , coagulopathy ( Platelet &lt; 100/nl , activate partial thromboplastin time , aPTT ) &gt; 80sec , serum creatinine &gt; 1.2 mg/dl , respiratory disease ( asthma , COPD , PaO2 &lt; 70 mmHg , pulmonary hypertension pulmonary edema , etc ) consent trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>